Pressure BioSciences (OTCQB: PBIO), today announced a collaboration with SinuSys Corporation aimed at evauating the potential for PBI’s innovative Ultra Shear Technology(TM) (“UST”) platform to strengthen the effectiveness of SinuSys Corp’s lead product candidate Restora. Depending on the outcome of the collaboration, SinuSys plans to license PBI’s UST platform for use with Restora on its path to FDA approval in a phase IIb clinical study later this year. PBIO is a leader in the development and sale of broadly enabling, pressure-based instruments, consumables and platform technology services to the worldwide biotechnology, biotherapeutics and other industries. SinuSys Corporation is a medical device company focused on developing new therapies to improve the sinus health of patients. “Our patented UST platform is a unique breakthrough for nanoemulsification processing designed to resolve multiple substantive problems facing manufacturers of therapeutic drugs, nutraceuticals, and other products containing hydrophobic (water repelling) active ingredients that are at best poorly soluble in water,” said PBI chief science officer Dr. Alexander V. Lazarev in the press release. “Poor water solubility results in lower absorption rates and requires much higher loading of the active compounds into products to achieve targeted dosing and bioavailability of active ingredients for the patient. Unfortunately, poor water solubility also carries overdosing risks in conventional emulsions due to oil and water phases further separating and leading to non-uniform drug distribution. Scientific publications have demonstrated that hydrophobic active ingredients manufactured into high-quality nanoemulsions with droplet sizes of less than 100 nanometers can facilitate increased absorption and bioavailability while lowering doses and improving controlled release. This should result in better quality products and treatment experiences for the patient, with overall reduction in product costs.”
To view the full press release, visit https://nnw.fm/YF80m
About Pressure BioSciences Inc.
Pressure BioSciences is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. PBIO’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented-enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). The company’s primary focus is on the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of PBIO’s pressure-based technologies in the following areas: (1) the use of its recently acquired, patented technology from BaroFold Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of its recently patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room-temperature, stable, low-acid liquid foods that cannot be effectively preserved using existing nonthermal technologies. For more information, visit the company website at www.PressureBioSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://nnw.fm/PBIO
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork
